Beta‐site APP‐cleaving enzyme 1 (BACE1), the rate‐limiting enzyme in Aβ generation,[6] is a critical biomarker for early AD pathology, preceding Aβ deposition[7, 8] and correlating with progression from mild cognitive impairment (MCI) to AD.[9] Many clinical trials of AD treatment have shown that interventions at the MCI stage are usually effective.[10] BACE1 detection is vital for the early treatment of AD. This evidence concerns the gene BACE1 and Cognitive impairment.